Hat mitgewirkt an:
-
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
-
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
-
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
-
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib